Senores Pharma Q2 & H1 FY27: Revenue & EBITDA Hit Record Highs
Senores Pharmaceuticals reported record Q2 & H1 FY27 revenue and EBITDA. Q2 revenue grew 25% Y-o-Y to ₹192 crore, with EBITDA up 38% to ₹58 crore. H1 revenue rose 30% to ₹372.5 crore, and EBITDA increased 58% to ₹111 crore. PAT grew 22% (Q2) and 31% (H1). The company reaffirmed FY27 guidance for 30-40% revenue growth and 50-60% PAT growth.
The announcement details strong financial performance with record revenues and EBITDA, significant growth in key business segments like regulated markets, and reaffirmation of ambitious future guidance. The expansion of the ANDA portfolio and upcoming product launches are significant positive developments.
The company reported record revenue and EBITDA, exceeding previous guidance and demonstrating strong year-on-year growth across key financial metrics. The expansion of the ANDA portfolio and upcoming product launches indicate positive future prospects.
Senores Pharmaceuticals Limited announced strong financial results for the second quarter (Q2) and first half (H1) of FY27, achieving their highest-ever quarterly revenue and EBITDA. Revenue saw a year-on-year growth of 25% in Q2 and 30% in H1 FY27, while EBITDA increased by 38% and 58% respectively. Profit After Tax (PAT) registered healthy growth of 22% in Q2 and 31% in H1 FY27.
The company's regulated market business demonstrated robust growth, with a 28% Y-o-Y increase in Q2 and 34% in H1 FY27. This was driven by a significant expansion of their ANDA portfolio, which grew from 34 in September 2025 to 64 in September 2026, with 23 already commercialized. In Q2 FY27, Senores received approval for one new ANDA and three sANDAs, with plans to launch the new ANDA in Q3 FY27.
Looking ahead, the company anticipates meaningful acceleration in the second half of FY27 (H2 FY27) driven by their CMO/CDMO front, supported by established marketing partnerships and manufacturing capacities. Investments in R&D for complex and specialty products have also expanded their molecule pipeline to 41 newly developed molecules.
Historically, H2 has been stronger than H1 for Senores, a trend expected to continue in FY27. The company anticipates contributions from Amerisyn and Zoraya to commence from H2 FY27, providing additional growth drivers. The CDMO/CMO business is also progressing well, with a pipeline expected to translate into business over the next 12 months.
Emerging market business revenue grew by approximately 21% in Q2 and 25% in H1 FY27, with improving profitability and turning cash positive. The European PIC/S approval in H1 FY27 is expected to further strengthen regulatory credentials in emerging markets.
Financially, consolidated revenue from operations for Q2 FY27 stood at ₹192 crores, and for H1 FY27 at ₹372.5 crores. Consolidated EBITDA for Q2 FY27 was ₹58 crores with a 30% EBITDA margin, and for H1 FY27 it was ₹111 crores, also at nearly 30% margin. Profit after tax for Q2 FY27 was around ₹36.6 crores, and for H1 FY27 it was ₹67 crores.
The company reaffirmed its FY27 guidance of 30% to 40% revenue growth and 50% to 60% PAT growth. Beyond FY27, Senores expects to sustain an annual growth rate of around 25% over the next 2 to 3 years.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.